INEBIR and ANSEDH sign key agreement to improve genetic diagnosis and support for patients with Ehlers-Danlos Syndrome. This collaboration seeks to offer priority access to advanced genetic testing, preferential conditions for ANSEDH members, and the promotion of new lines of biomedical research focused on rare diseases such as EDS.
Table of Contents
- 1 What does this agreement cover?
- 2 Who is ANSEDH and what is its mission?
- 3 Why is this collaboration important?
- 4 Benefits for patients with EDS or collagenopathies
- 5 What is Ehlers-Danlos Syndrome?
- 6 Why is early diagnosis of Ehlers-Danlos syndrome essential?
- 7 Genetic diagnosis at Inebir
- 8 Preferential conditions for ANSEDH members
- 9 Frequently asked questions about the agreement between Inebir and ANSEDH for patients with Ehlers-Danlos Syndrome
- 9.1 What does the collaboration between Inebir and ANSEDH consist of?
- 9.2 What benefits does this agreement bring to Inebir patients?
- 9.3 What is Ehlers-Danlos Syndrome and what are its most common symptoms?
- 9.4 How can Inebir help me if I have Ehlers-Danlos Syndrome?
- 9.5 Who can access the services of the agreement between Inebir and ANSEDH?
What does this agreement cover?
The agreement aims to offer real solutions to people affected by Ehlers-Danlos Syndrome and other inherited collagenopathies. The alliance between INEBIR and ANSEDH guarantees access to precision genetic diagnostics, tailored reproductive guidance, and clinical counseling in medical genetics.
Who is ANSEDH and what is its mission?
ANSEDH It is the National Association for Ehlers-Danlos Syndrome, Hypermobility, and Collagenopathies. For over a decade, it has been working to to raise awareness of these rare diseases, supporting patients and families throughout the entire process—from diagnosis to daily life—and to promote clinical and scientific research that will improve knowledge, early detection and quality of life for affected individuals.
Why is this collaboration important?
Thanks to this agreement, it will be possible to:
- Reduce clinical and genetic diagnosis times.
- Facilitate access to advanced molecular testing.
- Establish a framework for applied scientific collaboration.
- Develop reproductive monitoring protocols and genetic counseling.
Benefits for patients with EDS or collagenopathies
Members of ANSEDH will have preferential access to specialized genetic studies conducted at Inebir, a clinical evaluation based on medical genetics, and access to a specialized gynecological consultation. They will also be able to participate in ongoing research projects focused on early diagnosis and phenotypic characterization.
What is Ehlers-Danlos Syndrome?
Ehlers-Danlos syndrome (EDS) comprises a group of genetic disorders that affect the body's connective tissue. It can involve abnormalities in the skin, joints, blood vessels, and internal organs. It is an underdiagnosed condition that requires a multidisciplinary medical approach.
Why is early diagnosis of Ehlers-Danlos syndrome essential?
Identify early on the Ehlers-Danlos syndrome It allows patients to make informed decisions about their reproductive health and plan for preventative treatments. Early diagnosis also facilitates access to collagen disease specialists and improves the patient's overall prognosis.
Main symptoms of EDS
- Joint hypermobility
- Chronic musculoskeletal pain
- persistent fatigue
- Fragility or abnormal elasticity of the skin
- Dysautonomia
- Vascular risk in specific subtypes
Genetic diagnosis at Inebir
Inebir, as a reproductive medicine center with medical genetics unit, It has advanced molecular tools to identify mutations related to inherited collagenopathies. This diagnostic capability allows for the confirmation of clinical suspicions, guides reproductive counseling, and helps prevent future complications.
Preferential conditions for ANSEDH members
Under this agreement, Inebir offers special rates on clinical genetics and reproductive counseling services for individuals affiliated with ANSEDH. For more details, please contact the center directly.
Frequently asked questions about the agreement between Inebir and ANSEDH for patients with Ehlers-Danlos Syndrome
What does the collaboration between Inebir and ANSEDH consist of?
Both entities will work together to improve early diagnosis, promote biomedical research and offer comprehensive support to those living with hypermobility, collagenopathies and rare diseases.
What benefits does this agreement bring to Inebir patients?
Patients will have access to advanced genetic analysis, specialized gynecological consultation, preferential care conditions and participation in joint research lines developed by Inebir and ANSEDH.
What is Ehlers-Danlos Syndrome and what are its most common symptoms?
Ehlers-Danlos syndrome (EDS) is a group of genetic connective tissue disorders. Common symptoms include joint hypermobility, chronic pain, fatigue, skin fragility, and vascular risk. It requires specialized medical care and a multidisciplinary approach.
How can Inebir help me if I have Ehlers-Danlos Syndrome?
Inebir offers genetic testing, personalized clinical follow-up, and reproductive counseling. It also collaborates with ANSEDH and external specialists to ensure comprehensive care.
The disease has multiple genetic causes; Inebir collaborates in the investigation of new mutations that cause the disease.
Who can access the services of the agreement between Inebir and ANSEDH?
Anyone associated with ANSEDH, as well as patients with clinical suspicion of EDS or collagenopathies, can benefit from the agreement and request priority care.
If you have symptoms consistent with Ehlers-Danlos syndrome, or are a member of ANSEDH and would like more information about genetic diagnosis, contact with our specialized Inebir team for personalized attention.
Follow us on our social networks: Facebook, X, LinkedIn, TikTok, Social media coordinator y YouTube.
